



## **Lundbeck to Present Data on Alzheimer's, Epilepsy and Movement Disorder Medicines at AAN**

*Data Include Two Oral Presentations on Approved Therapies for Challenging Seizures and One Oral Presentation on an Investigational Compound for Alzheimer's Disease*

*An Additional 18 Poster Presentations Showcase Lundbeck's Neurology Medicines*

**Vancouver, CANADA, April 11, 2016** – Lundbeck announced today that data on its currently available and investigational neurology medicines will be presented at the 2016 American Academy of Neurology (AAN) Annual Meeting in Vancouver, Canada, on April 15-21, 2016. Of the 21 abstracts on Lundbeck medicines, three have been accepted for oral presentation.

“Lundbeck strives to be a world leader in advancing therapies for people with psychiatric and neurological conditions,” said Jason Bradt, MD, MBA, MHA, Vice President of Lundbeck U.S. Medical Affairs. “Developing therapies for brain disorders is an incredibly complex process. The depth of our scientific presentations at AAN showcases our unwavering commitment to understanding the intricacies of the brain and translating this knowledge in ways that help us improve upon our currently approved and pipeline medicines.”

Lundbeck data to be presented at AAN include the following highlights:

### **Epilepsy**

Post Hoc Analyses from an Open-Label Extension Study with clobazam

- Location/Date: Oral Platform Presentation Session S14 – Epilepsy: Antiepileptic Drugs and Epidemiology, Sunday, April 17, 1:15 - 1:30 p.m.

Retinal Structure and Function in Adult Patients with Refractory Complex Partial Seizures (rCPS) Treated with vigabatrin

- Location/Date: Oral Platform Presentation Session S14 – Epilepsy: Antiepileptic Drugs and Epidemiology, Sunday, April 17, 1:45 - 2 p.m.

### **Alzheimer's Disease**

A 5-HT<sub>6</sub> antagonist as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease (Phase II results for investigational compound, idalopirdine)

- Location/Date: Oral Clinical Trials Plenary Session, Wednesday, April 20, 9 - 11 a.m.

### **Neurogenic Orthostatic Hypotension (nOH)**

Ten poster presentations focusing on Lundbeck's therapy for symptomatic neurogenic orthostatic hypotension (nOH).

- nOH is a rare disease caused by an underlying neurologic condition such as Parkinson's disease, multiple system atrophy, or pure autonomic failure.
- Locations/Dates:
  - o 1 presentation during poster session P1, Saturday, April 16, 8:30 a.m. - 7 p.m.
  - o 1 presentation during poster session P2, Sunday, April 17, 8:30 a.m. - 5:30 p.m.
  - o 8 presentations during poster session P5, Wednesday, April 20, 8:30 a.m. - 7 p.m.

Follow @LundbeckUS on Twitter throughout the meeting for updates, reminders and news regarding data presentations, as well as other professional and patient-focused initiatives.

### **About Lundbeck**

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of research within neuroscience. The key areas of focus are Alzheimer's disease, depression, Parkinson's disease and psychosis.

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this *Progress in Mind*.

Our approximately 5,500 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 3.9 billion; USD 6.4 billion).

In the U.S., Lundbeck employs nearly 1,000 people focused solely on accelerating therapies for brain diseases. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in hundreds of initiatives each year that support our patient communities. To learn more, visit us at [www.LundbeckUS.com](http://www.LundbeckUS.com).

### **CONTACT:**

Rachel Vann  
Lundbeck  
Public Relations, Senior Manager  
(847) 282-1139  
[rvan@lundbeck.com](mailto:rvan@lundbeck.com)